Overview

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Evaluation of the pharmacokinetics (PK) of SPR206 in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Spero Therapeutics
Collaborators:
Iqvia Pty Ltd
United States Department of Defense